The goal is ultimately, to prevent or reverse drug resistance, as well as providing gene signatures that could preemptively reveal potential resistance and sensitivity to combinatorial treatment plans, in women diagnosed with HER+ or ER+ breast cancer. Here, ESR1 is linked to breast carcinoma.